Biological Database Mining for LLM-Driven Alzheimer’s Disease Drug Repurposing
Preprint
Abstract
BACKGROUND: This study presents a software pipeline that leverages LLMs to apply knowledge stored in natural language (such as in pharmacological texts) and ontologies in a transparent Drug Repurposing (DR) information structure. METHODS: Alzheimer’s Disease (AD) related entries in Gene Ontology and DrugBank were integrated into a Knowledge Graph database to inform LLM prompts. 16,581 drugs were screened for their DR potential by the LLM Llama3:8b. The vector embedding representation of the drugs in the LLM was investigated to asses if LLMs store pharmacological information in alignment with domain expert understanding of pharmacological groups. By measuring the semantic similarity of drugs quantitatively, the performance of the DR pipeline was examined. A manual hallucination check was performed to assess the impact of the ontology-database combination on LLM-hallucination performance. The results were compared against registered clinical trials (RCTs) and proposed medications in meta-analyses to evaluate their predictive value. RESULTS: The embedding analysis showed that the vector representations of drugs in the LLM show clusters in alignment with pharmacological groups. The ontologically enhanced prompt was closer to the expert domain proposals than a zero-shot control prompt without that knowledge. The results of the ontology-based prompt showed fewer hallucinations in their responses compared to the zero-shot control prompting. CONCLUSIONS: Ontology-augmented LLM interaction leads to fewer hallucinations and output closer to expert assessment in comparison with a zero-shot control. We propose retrospective analyses, considering the high-rated drugs and their effect on AD patients as a starting point for further (prospective) research.Keywords
Funding Information
- Virtual Research Environment at the Charité Berlin a node of EBRAINS Health Data Cloud (101147319)
- Virtual Brain Twin (101137289)
- EBRAINS-PREP (101079717)
- AISN (101057655)
- eBRAIN-HEALTH (101058516)
- Digital Europe TEF-Health (101100700)
- EU H2020 Virtual Brain Cloud (826421)
- Human Brain Project SGA2 (785907)
- Human Brain Project SGA3 (945539)
- German Research Foundation SFB 1436 (425899996)
- SFB 1315 (327654276)
- SFB 936 (178316478)
- SFB-TRR 295 (424778381)
- SPP Computational Connectomics RI 2073/6-1
- RI 2073/10-2
- RI 2073/9-1
- DFG Clinical Research Group BECAUSE-Y (504745852)
- PHRASE Horizon EIC grant (101058240)
This publication has 57 references indexed in Scilit:
- Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotesAlzheimer's & Dementia, 2023
- Artificial intelligence for dementia drug discovery and trials optimizationAlzheimer's & Dementia, 2023
- Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancerThe Breast, 2022
- Drug repurposing strategy for treating Alzheimer’s diseaseAlzheimer's & Dementia, 2021
- Drug repurposing for Alzheimer’s disease: Selective serotonin reuptake inhibitorsAlzheimer's & Dementia, 2020
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)JAMA, 2020
- Drug repurposing: a promising tool to accelerate the drug discovery processDrug Discovery Today, 2019
- Therapeutic Vaccines for Hypertension: a New Option for Clinical PracticeCurrent Hypertension Reports, 2018
- Differential tissue and ligand-dependent signaling of GPR109A receptor: Implications for anti-atherosclerotic therapeutic potentialCellular Signalling, 2013
- A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophreniaEuropean Neuropsychopharmacology, 2012